SomaLogic (SLGC) customer map: contracts, concentration and the Illumina inflection

SomaLogic monetizes a proprietary proteomics platform (SomaScan®) by charging for sample processing, advanced proteomic assays, and long-term research partnerships with pharmaceutical, healthcare and national-scale research programs. Revenue is driven by service throughput and multi-year contracts that convert lab capacity into recurring scientific collaborations, while strategic partnerships and an acquisition by Illumina reshape go-to-market and scale economics. Explore the customer footprint and implications for investors at https://nullexposure.com/.

How the business actually gets paid

SomaLogic sells a mix of laboratory services (assays run on the SomaScan platform), data packages that support translational research, and partnership agreements with large pharma and institutional research groups. The company’s reported TTM revenue was $81.7 million with a market capitalization around $396 million, but the business ran at a loss in the latest TTM with negative gross profit and negative EBITDA, so customer contract quality and duration determine near-term cash flow resilience.

• Contracting posture: The company’s customer base includes long-term agreements that extend the commercial life of its platform and provide sample-volume visibility.
• Concentration: Large institutional partners generate outsized sample volumes and revenue; this creates both revenue visibility and single-counterparty concentration risk.
• Criticality: For clients that designate SomaLogic as their primary proteomics provider, the platform functions as a mission-critical research input rather than an interchangeable commodity.
• Maturity: Repeat sample volumes and decade-long contract terms indicate the platform has moved beyond proof-of-concept to durable commercial deployments.

If you want a concise map of these customer relationships and how they affect valuation, see our site: https://nullexposure.com/.

What investors need to see: the customer roster, one relationship at a time

Group 42 Healthcare

Group 42 Healthcare signed an agreement naming SomaLogic as its sole proteomics provider for a multi‑omic research and healthcare initiative, giving SomaLogic direct access to an international research program and expanding its geographic reach. According to a company press release published on Yahoo Finance (March 10, 2026), Group 42 will use SomaLogic for that global initiative: https://finance.yahoo.com/news/somalogic-announces-preliminary-full-2022-140000403.html.

Novartis (listed as Novartis / NVS)

Novartis extended its long-term contract to keep SomaLogic as its primary proteomics platform through 2033, reflecting deep integration into translational research workflows and a history of high sample throughput. A Yahoo Finance release (March 10, 2026) reports SomaLogic has processed over 150,000 samples for Novartis from 2019–2022 under the agreement, underscoring significant historical volume and future revenue visibility: https://finance.yahoo.com/news/somalogic-announces-preliminary-full-2022-140000403.html.

Duplicate Novartis entry (NVS)

The dataset includes a second entry for Novartis (NVS) repeating the contract extension and the 2033 primary-platform designation, supporting the inference that Novartis occupies a structurally large position in SomaLogic’s customer mix. The same March 2026 Yahoo Finance announcement documents this extension and historical sample volume: https://finance.yahoo.com/news/somalogic-announces-preliminary-full-2022-140000403.html.

Illumina (ILMN)

Illumina publicly stated that it completed the acquisition of SomaLogic, framing the transaction as a natural extension of a long-standing partnership between the two companies; this converts a strategic customer/partner relationship into full corporate ownership. The comment appears in the Q4 2025 Illumina earnings call transcript as published by InsiderMonkey and reviewed in March 2026: https://www.insidermonkey.com/blog/illumina-inc-nasdaqilmn-q4-2025-earnings-call-transcript-1690265/.

Why these relationships matter for valuation and risk

• Revenue visibility from long contracts: Novartis’ extension through 2033 and documented multi-year sample volumes provide a rare line of sight for a lab-services growth story; long-dated contracts materially reduce near-term revenue volatility compared with one-off research projects. The Novartis data point (150k samples processed 2019–2022) is a concrete indicator of scale in a single enterprise account.
• Concentration risk: A handful of large partners contribute disproportionate volumes. That concentration supports margin leverage when volumes scale, but it creates single-counterparty risk if a strategic partner changes providers or consolidates internally.
• Strategic optionality from acquisition: Illumina’s acquisition removes independence and has direct implications for future channel strategy, capital allocation and integration synergies. As owner, Illumina can accelerate product bundling and commercial distribution but also shifts customer dynamics—partners that once bought services now transact within a larger corporate ecosystem.
• International expansion: The Group 42 Healthcare sole-provider agreement signals a push into national-scale, multi‑omic initiatives—a higher-margin, higher-visibility client type that can bolster credibility in government and healthcare markets.

Financial context that frames customer value

SomaLogic’s $81.7M revenue TTM contrasts with negative gross profit and EBITDA, indicating that current commercial traction has not yet converted into scaled profitability. Customer quality and contract tenor will determine whether incremental volume converts to operating leverage or whether continued capital investment is necessary to sustain service levels. The Illumina acquisition introduces a capital and distribution partner that changes the marginal economics of scaling. Use caution when projecting margin inflection until post-acquisition integration plans are disclosed.

Practical takeaways for investors and operators

• Positive: Long-term, high-volume contracts (Novartis) and exclusive provider arrangements (Group 42) are durable revenue anchors that justify premium valuation if Illumina executes on scale efficiencies.
• Negative: Customer concentration and existing negative gross margins require monitoring; the business is still cash-intensive relative to its market cap.
• Strategic: Illumina ownership is the single most material event for customers and investors—expect changes in pricing, bundling and channel access that will reprice SomaLogic’s service economics.

For a deeper, investor-grade customer map and scenario analysis, visit https://nullexposure.com/ and review our coverage of partner concentration and contract timelines.